MTPConnect Backs Start-ups In Heart Disease and Diabetes through New $28.5M TTRA Investment
Posted: 3 September 2024 MTPConnect will inject much-needed funding and support for Australian small to medium enterprises (SMEs) to commercialise innovative medical products to better treat cardiovascular disease and diabetes when it rolls out new investment through its…
New funds to Embrace rare genetic disorder research
Posted: 3 September 2024 Scientists at La Trobe University have received nearly $140,000 from rare disease charity Archie’s Embrace to investigate an under-researched genetic disorder which causes early-onset neurodegeneration in babies. The disorder, which causes a deficiency of…
Non-invasive testing a way of the future
Posted: 3 September 2024 A new collaborative study between the RMH and WEHI is the latest technology to test for early markers of kidney rejection via a simple urine test, hoping to bypass the need for invasive biopsies. Researchers at the RMH and WEHI are…
New clue into the curious case of our ageing immune system
Posted: 3 September 2024 A WEHI study could help solve a long-standing mystery into why a key immune organ in our bodies shrinks and loses its function as we get older. The thymus is an organ essential for…
Two-in-one breakthrough: Cutting-edge immunotherapy could hold promise for incurable brain cancer
Posted: 3 September 2024 Researchers at WEHI have identified a promising new two-in-one treatment that not only targets and destroys an aggressive form of brain cancer, but also helps the immune system develop a lasting defence against it. This…
Scientists discover how the body’s killer cells attack cancer
Posted: 3 September 2024 An international team of scientists are on the verge of a cancer breakthrough after working out how the body’s immune system targets cells devastated by the disease. A new study published in the journal Science…
Telix Submits NDA for TLX101-CDx (Pixclara®) Brain Cancer Imaging Agent
Posted: 28 August 2024 Telix today announces it has submitted a New Drug Application (NDA) to the United States (U.S.) Food and Drug Administration (FDA) for TLX101-CDx, (Pixclara®[1], 18F-floretyrosine or 18F-FET), an investigational PET[2] agent for the characterisation of progressive or…
Finger-prick test could screen for early Alzheimer’s
Posted: 28 August 2024 GPs could soon be able to screen their patients for Alzheimer’s Disease (AD) using a simple handheld device developed by Monash engineers. Monash engineers have developed the first-of-a-kind finger-prick blood test with ‘needle-in-a hay-stack’…
Life prolonging breast cancer drug receives expanded access on the PBS
Posted: 28 August 2024 Australians diagnosed with a type of metastatic breast cancer will now have access to a life prolonging treatment under the Pharmaceutical Benefits Scheme (PBS) from 1 September 2024. Trastuzumab deruxtecan (Enhertu®) will be expanded on…
$66 million in 10 years: groundbreaking strategic investment fund to drive biomedical innovation
Posted: 28 August 2024 With a grand vision of investing $66 million over 10 years in groundbreaking medical innovations, WEHI’s first strategic investment fund, 66ten, is the largest internal pre-seed and seed fund created by an Australian medical…
Delivery of New Colorectal Cancer Multiplex Assay Alpha Kit
Posted: 28 August 2024 Transformative, predictive cancer diagnostics technology company, Rhythm Biosciences Ltd (ASX: RHY) (Rhythm or the Company) advises it has received the first batch of the Alpha version of the multiplex antibody detection kits developed and…
Lumos Diagnostics seals deal to advance point-of-care test to monitor liver health
Posted: 27 August 2024 Lumos Diagnostics (ASX:LDX) has extended its existing deal with the Burnet Diagnostics Initiative to progress a new point-of-care test for use in monitoring liver health in an upcoming clinical trial. As part of the deal,…
